Amgen Inc.
NASDAQ:AMGNDrug Manufacturers - General
-$6.93 today
- Market cap
- $240.11B
- Beta
- 0.42
- P/E (TTM)
- 23.2
- EPS (TTM)
- $14.44
- Dividend yield
- 2.93%
Volume 2.58M
Average 2.76M
AMGN Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Amgen Inc.NASDAQ: AMGN
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables growth accelerates
Q2 FY2026 accounts receivables of $1.09B (cash outflow) rose 112.2% year over year, ahead of the -9.4% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +53.1% a year.
Context
- Accounts receivables amounted to 7.3% of revenue in FY2025, up 6.0 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +112.2% holds above the trailing-twelve-month pace of -9.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (2.68B) USD
- Year-over-year change
- -706.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.68B) | -706.8% |
| FY2024 | 2024-12-31 | 441M | +143.4% |
| FY2023 | 2023-12-31 | (1.02B) | -36.1% |
| FY2022 | 2022-12-31 | (746M) | -73.9% |
| FY2021 | 2021-12-31 | (429M) | — |
Accounts Receivables vs competitors
How AMGN compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -9.4% is the lowest of 5, against a peer median of +35.3%.
- Accounts receivables amounts to 4.0% of revenue for AMGN, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.53B USD | -9.4% | +53.1% | 4.0% | |
| LTM Sep 2026 | $1.37B USD | +3.7% | +11.4% | 1.4% | |
| LTM Jun 2026 | $1.28B USD | +66.8% | +0.8% | 2.0% | |
| LTM Jun 2026 | $1.09B USD | — | +19.2% | 1.6% | |
| LTM Jun 2026 | $678M USD | +102.4% | -23.7% | 1.4% | |
| LTM Jun 2026 | $672.78M USD | -6.6% | +41.7% | 1.2% | |
| LTM Jun 2026 | $0 USD | — | +185.9% | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | £0 GBP | — | — | 0.0% | |
| Peer median (excluding AMGN) | — | +35.3% | +15.3% | 1.2% | |
Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.89B | 6.55B | 6.72B | 4.09B | 7.71B |
| Depreciation & Amortization | 3.4B | 3.42B | 4.07B | 5.59B | 5.17B |
| Deferred Income Tax | (453M) | (1.2B) | (1.27B) | (1.23B) | (721M) |
| Stock-Based Compensation | 341M | 401M | 431M | 530M | 494M |
| Change in Working Capital | (1.19B) | (733M) | (484M) | 2.37B | (1.98B) |
| Accounts Receivables | (429M) | (746M) | (1.02B) | 441M | (2.68B) |
| Inventory | (165M) | (742M) | 491M | 2.53B | 886M |
| Accounts Payables | (69M) | 154M | (402M) | 312M | 428M |
| Other Working Capital | (531M) | 601M | 442M | (920M) | (616M) |
| Other Non-Cash Items | 1.28B | 1.28B | (991M) | 141M | (715M) |
| Operating Cash Flow | 9.26B | 9.72B | 8.47B | 11.49B | 9.96B |
| Capital Expenditures | (880M) | (936M) | (1.11B) | (1.1B) | (1.86B) |
| Acquisitions (Net) | (2.69B) | (3.73B) | (26.99B) | 0 | (53M) |
| Purchases of Investments | (8.9B) | (2.59B) | (1M) | 0 | 0 |
| Sales of Investments | 13.23B | 1.22B | 1.67B | 0 | 0 |
| Other Investing Activities | (35M) | (12M) | 225M | 50M | (32M) |
| Investing Cash Flow | 733M | (6.04B) | (26.2B) | (1.05B) | (1.94B) |
| Debt Repayment | 795M | 6.62B | 25.68B | (4.26B) | (5.68B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (4.98B) | (6.36B) | 0 | (200M) | 0 |
| Dividends Paid | (4.01B) | (4.2B) | (4.56B) | (4.83B) | (5.12B) |
| Other Financing Activities | (78M) | (103M) | (72M) | (124M) | (52M) |
| Financing Cash Flow | (8.27B) | (4.04B) | 21.05B | (9.42B) | (10.86B) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.72B | (360M) | 3.32B | 1.03B | (2.84B) |
| Free Cash Flow | 8.38B | 8.79B | 7.36B | 10.39B | 8.1B |
Amgen Inc.
NASDAQ:AMGN
Intrinsic Alpha fair value
Locked
Current Price
$443.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.